Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Incorporated (NYSE: TFX) is a global medical technology company whose news flow reflects its activity across anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. Company announcements frequently highlight portfolio developments, clinical research, financial performance, and governance changes, giving investors and healthcare professionals insight into how the business is evolving.
Recent Teleflex news has included leadership transitions, with the Board appointing a long-serving director as Interim President and Chief Executive Officer and naming a new Chair of the Board, as well as updates on the search for a permanent CEO. The company has also reported on strategic portfolio actions, such as agreements to sell its Original Equipment Manufacturing and Development Services business and its acute care and interventional urology segments, reflecting a shift toward a more focused organization centered on core critical care and high-acuity hospital markets.
On the operational side, Teleflex regularly issues quarterly earnings releases and outlook updates, detailing revenue by region and global product category, along with commentary on non-GAAP measures like adjusted revenue and adjusted constant currency revenue growth. Dividend declarations and share repurchase authorizations are also communicated through press releases and associated SEC filings.
For those following clinical and product developments, Teleflex news covers topics such as the launch of the Barrigel™ rectal spacer in new markets and support for investigator-initiated trials like the DUBSTENT DIABETES study in interventional cardiology. Visitors to this TFX news page can review these updates in one place to understand how Teleflex’s strategy, portfolio, and financial profile are changing over time.
Teleflex (NYSE: TFX) announced a new agreement with Premier®, Inc. for its Titan SGS® powered stapling device, designed for sleeve gastrectomy procedures. This collaboration enables Premier members to access competitive pricing on the Titan SGS®, which is uniquely indicated for gastric pouch creation. The device has proven to cut staple time in half and facilitates consistent gastric anatomy, boasting a 23cm staple line. Over 6,000 procedures have utilized the Titan SGS® since its 2021 launch. Teleflex's partnership with Premier is expected to enhance the distribution of this advanced surgical technology nationwide.
Teleflex (NYSE: TFX) has launched a national advertising campaign to promote the UroLift® System, an innovative, minimally invasive treatment for benign prostatic hyperplasia (BPH). This humorous campaign emphasizes the importance of health screenings for men and aims to encourage visits to urologists. BPH, which affects many aging men, can cause disruptive urinary symptoms. The UroLift® System has treated over 400,000 men globally, offering a solution without severe side effects like erectile dysfunction. The 5-year durability data shows a 2-3% surgical retreatment rate annually.
Teleflex, a global provider of medical technologies, announced that Liam Kelly, its Chairman, President, and CEO, will speak at the 41st Annual J.P. Morgan Healthcare Conference. The event is set for January 10, 2023, at 3:00 p.m. PT in San Francisco, California. A live audio webcast and presentation slides will be accessible on the Teleflex investor website. Teleflex focuses on innovative solutions in various medical fields, including vascular access and emergency medicine. More information can be found at teleflex.com.
Summary not available.
Liam Kelly, Chairman, President and CEO of Teleflex, will present at the 34th Annual Piper Sandler Healthcare Conference in New York on November 30, 2022, at 1:30 p.m. (ET). A live audio webcast of the presentation can be accessed via the investor section of the Teleflex website. Teleflex specializes in medical technologies that enhance health and quality of life, with innovative solutions in vascular access, interventional cardiology, anesthesia, and more. For additional details, visit teleflex.com.
Teleflex (NYSE: TFX) has announced a worldwide recall of specific lots of its Gibeck® Iso-Gard® Filters due to potential risks including splitting or detaching during use, which could compromise patient air supply. The recall, which affects products manufactured between December 17, 2019, and March 26, 2022, was expanded after 38 complaints were reported, including 4 injuries related to patient desaturation, but no deaths or long-term injuries. The FDA classified the recall as Class I, indicating serious health risks associated with the affected filters.
Teleflex, a global provider of medical technologies, announced that Liam Kelly, Chairman, President and CEO, will present at the Jefferies London Healthcare Conference on November 15, 2022, at 2:40 p.m. (GMT). A live audio webcast of the presentation will be accessible via the investor section of the Teleflex website. The company focuses on purpose-driven innovation to enhance healthcare, with a diverse portfolio that includes products for vascular access, interventional cardiology, and more. For more details, visit teleflex.com.
Teleflex announced a quarterly cash dividend of $0.34 per share, payable on December 15, 2022 to shareholders on record by November 15, 2022. This decision underscores the company’s commitment to shareholder returns while continuing its focus on providing medical technologies that enhance patient care.
Teleflex announced Q3 2022 financial results with revenues of $686.8 million, representing a 1.9% decline year-over-year, partially offset by a 2.4% increase in constant currency. GAAP diluted EPS dropped to $2.16 from $4.20 in the prior year. The company lowered its GAAP revenue growth guidance to (0.75)% to 0.25% and adjusted diluted EPS guidance to $12.80 to $13.20. The acquisition of Standard Bariatrics aligns with its M&A strategy, contributing to revenue and margin growth.
Teleflex (NYSE: TFX) announced results from a new study published in the Journal of Endourology demonstrating that the UroLift® System is effective for treating benign prostatic hyperplasia (BPH), specifically in patients with obstructive median lobes. Compared to TURP, patients treated with UroLift experienced significantly greater symptom improvement, faster satisfaction, and fewer post-op catheterizations. The analysis combined outcomes from controlled trials and real-world settings, confirming the safety and effectiveness of the UroLift System.